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VaccineRabies is a fatal zoonotic disease preventable through timely and adequate post-exposure prophylaxis
(PEP) to potentially exposed persons i.e. wound washing and antisepsis, a series of intradermal (ID) or
intramuscular (IM) rabies vaccinations, and rabies immunoglobulin in WHO category III exposures.
The 2010 WHO position on rabies vaccines recommended PEP schedules requiring up to 5 clinic visits
over the course of approximately one month. Abridged schedules with less doses have potential to save
costs, increase patient compliance, and thereby improve equitable access to life-saving PEP for at-risk
populations. We systematically reviewed new evidence since that considered for the 2010 position paper
to evaluate (i) the immunogenicity and effectiveness of PEP schedules of reduced dose and duration; (ii)
new evidence on effective PEP protocols for special populations; and (iii) the effect of changing routes of
administration (ID or IM) during a single course of PEP. Our search identified a total of 14 relevant stud-
ies. The identified studies supported a reduction in dose or duration of rabies PEP schedules. The 1-week,
2-site ID PEP schedule was found to be most advantageous, as it was safe, immunogenic, supported by
clinical outcome data and involved the least direct costs (i.e. cost of vaccine) compared to other sched-
ules. To supplement this evidence, as yet unpublished additional data were reviewed to support the
strength of the recommendations.
Evidence suggests that changes in the rabies vaccine product and/or the route of administration during
PEP is possible. Few studies have evaluated PEP schedules in persons with suspect or confirmed rabies
exposures. Gaps exist in understanding the safety and immunogenicity of novel PEP schedules in special
populations such as infants and immunocompromised individuals. Available data indicate that adminis-
tering rabies vaccines during pregnancy is safe and effective.
 2019 Published by Elsevier Ltd. This is an open access article under the CC BY IGO license. (http://crea-
tivecommons.org/licenses/by/3.0/igo/).1. Introduction
Rabies is a fatal disease caused by the rabies virus (RABV) and
other lyssaviruses and responsible for an estimated 59,000 human
deaths every year [1]. Up to 99% of human cases worldwide are
caused by dog bites [2]. Although there is no cure for clinical rabies,
the disease is readily preventable through timely provision of ade-
quate post-exposure prophylaxis (PEP).
PEP consists of thorough washing of the wound with water,
soap and application of antiseptics [3]; a series of rabies vaccina-tions; and administration of rabies immunoglobulins (RIG) or more
recently licenced monoclonal antibody products, if indicated [4].
The PEP protocol varies according to the category of exposure,
the immunological status of the patient and whether they have
been previously immunized against rabies [5]. As per 2010 recom-
mendations, a previously immunized person refers to a person
who has previously received rabies vaccine, either as a complete
pre- exposure prophylaxis course or as PEP. For persons who are
previously immunized against rabies, even decades earlier, RIG is
not indicated, and only booster injections are recommended [4].
These will invoke an anamnestic response and boost antibody
production.ination
2 J. Kessels et al. / Vaccine xxx (xxxx) xxxA rabies virus neutralizing antibody (RVNA) titre 0.5 IU/ml on
day 14 post-immunization with rabies vaccine is internationally
agreed as indicative of an adequate response to immunization. This
threshold is a surrogate used to measure the vaccine-induced sero-
conversion in studies of rabies vaccine efficacy and effectiveness
[5]. Rabies vaccines can be administered by the intradermal (ID)
or intramuscular (IM) route, depending on the schedule. Intrader-
mal rabies vaccination has been promoted by the World Health
Organization (WHO) since 1992. Its use can reduce the cost and
dose of vaccine by 60–80%, especially in high-throughput clinics
[6,7].
Although rabies vaccines are considered safe and highly
effective, WHO-recommended vaccine schedules of 2010 require
up to five clinic visits over approximately one month (see
Table 1) [4]. Due to the long duration of the schedule, persons
potentially exposed to rabies often do not complete the
full course of vaccination, with undetermined preventive
effectiveness.
The high cost of rabies PEP and potential loss of income due to
frequent travel to the clinic can pose a further barrier to treatment,
particularly in low- and middle-income countries [8–10]. Addi-
tionally, healthcare workers may be reluctant to fractionate vials
of rabies vaccine for patients if they are unsure the full volume will
be used before it should be discarded (i.e. within 6–8 h), which can
delay initiation of PEP. Shortages of rabies vaccines (and RIG) occur
frequently, particularly in small clinics in rural areas of developing
countries [11,12].
The 2010 WHO position paper [4] on rabies states that:
‘‘New PEP schedules, particularly those using ID administration,
even if shown to be safe and efficacious, must have clear prac-
tical or economic advantages, or both, over existing schedules if
they are to be endorsed.”
The long duration of the schedule also means that changes in
route of administration (IM to ID or vice versa) are likely to occur
in practice, e.g. where patients receive first or continuing vaccine
administration in a small clinic in a rural area (likely IM) after
referral to or from a larger clinic (likely ID). It is therefore also of
practical importance to assess the adequacy of the immune
response conferred by changes in the PEP administration route,
instead of beginning the schedule anew.
This systematic review on PEP aimed to inform the 2018 update
of the WHO position on rabies vaccines and rabies immunoglobu-
lins by evaluating: (i) the immunogenicity and effectiveness of PEP
schedules of reduced dose and duration; (ii) new evidence on
effective PEP protocols for special populations (immunocompro-
mised, pregnant women) and (iii) the effect of changing routes of
administration (ID or IM) during a single course of PEP on the
immunogenicity of PEP. The literature search is intended as anTable 1
Summary of the 2010 WHO-recommended PEP schedules (prior to the 2018 update). T
applicable).
Schedule Route Sites
WHO approved PEP schedules for non-previously immunized personsa
5-dose Essen (WHO 1992) IM (1-1-1-1-1
Zagreb 2-1-1 (WHO 1992) IM (2-0-1-0-1
Updated Thai Red Cross (TRC) (WHO 2005) ID (2-2-2-0-2
4-dose Essen (ACIP 2009)b IM (1-1-1-1-0
WHO approved expedited PEP schedules for previously immunized persons (booster)a
2-visit PEP ID/IM (1-1-0-0-0
Single day PEP ID (4-0-0-0-0
a As per the 2010WHO position, a previously immunized person referred to a person w
PEP.
b As per the 2010 WHO position, the 4-dose Essen schedule should be used only in
immunoglobulin, and WHO-prequalified rabies vaccines.
Please cite this article as: J. Kessels, A. Tarantola, N. Salahuddin et al., Rabies
schedules and the effect of changing administration routes during a single couupdate to the evidence review performed for the 2010 WHO rabies
vaccine position paper [4].
2. Methods
The literature review was performed according to PRISMA
guidelines for systematic reviews and meta-analyses [13]. We used
the following terms to conduct a database search of the PubMed
and Cochrane Database of Systematic Reviews (CDSR),
respectively:
(‘‘Rabies Vaccines”[nm] AND ‘‘Humans”[MeSH terms]) AND
(‘‘post-exposure”[title/abstract] OR ‘‘postexposure”[title/abstra
ct]) AND (‘‘2008/01/01”[PDAT]: ”3000/12/31”[PDAT])
and
#Rabies.
The search was conducted without language restrictions and
included articles published between January 2007 and June 2017
to reflect evidence published after the literature review for the
2010 WHO position paper on rabies was completed and as a con-
servative approach to capture evidence where records of exact
timeframes for previous literature reviews were lacking (Fig. 1)
[4]. Reference lists were screened for additional relevant literature
as supporting evidence for new PEP schedules, regardless of publi-
cation date. Relevant evidence from unpublished studies identified
through screening of grey literature and as submitted for consider-
ation by the Strategic Advisory Group of Experts on Immunization
(SAGE) working group on rabies was also assessed for inclusion
[14]. Titles and abstracts of all identified scientific publications,
as well as references of eligible reviews, were screened for inclu-
sion according to the criteria listed in Table 2.
3. Results
The literature search identified 13 relevant studies: seven stud-
ies relevant to PEP schedules of reduced doses/duration [15–21],
four studies on PEP protocols for patients with specific medical
conditions [22–25] and two studies relevant to changing the route
of vaccine administration or product during the same course of PEP
[26,27]. A then yet unpublished study from Cambodia with robust
data on an abridged PEP schedule was also identified and included
[28]. No direct evidence could be retrieved in support of an
abridged version of the Essen IM regimen (3 or less doses). Several
studies, including two cited in this publication [19,21], show
immunogenicity data at intervals over the course of the estab-
lished 4- or 5-dose IM PEP schedule as a comparator to investiga-
tional schedules.hese are recommended for persons with a category II or III exposure (plus RIG, if
Days Clinic visits Duration (days)
) 0, 3, 7, 14, 28 5 28
) 0, 7, 21 3 21
) 0, 3, 7, 28 4 28
) 0, 3, 7, 14 4 14
) 0, 3 2 3
) 0 1 1
ho can document previous complete course of pre-exposure vaccination or complete
healthy, immunocompetent patients who receive wound care, high quality rabies
post-exposure prophylaxis: A systematic review on abridged vaccination
rse, Vaccine, https://doi.org/10.1016/j.vaccine.2019.01.041
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833 records identified through search 
PubMed n = 829 
Cochrane library  n = 1 
Manual retrieval n = 3 
833 articles screened
800 articles excluded 
Excluded based on title n = 573 
Excluded based on abstract n = 227  
33 full-text articles assessed 
See inclusion/exclusion criteria 
20 articles excluded 
13 studies included in review and qualitative synthesis  
PEP schedules of reduced dose/ duration n = 7
Change in route of PEP administration n =  2 
modified PEP protocols for specific risk groups of rabies exposed patients n = 4
Fig. 1. PRISMA flow diagram showing the selection of studies on rabies post-exposure prophylaxis.
Table 2
Inclusion and exclusion criteria for evidence retrieved.
Inclusion criteria Exclusion criteria
Original studies Guidelines
Review articles Letters
Published in journals, books or websites Editorials
Reported on abridged rabies vaccine schedules Animal studies/basic
research
Included estimates of efficacy, effectiveness,
immunogenicity conferred by rabies
immunization
Reports on schedules
approved by WHO in 2010
J. Kessels et al. / Vaccine xxx (xxxx) xxx 33.1. PEP course duration and number of doses
A total of eight studies investigated the safety and immuno-
genicity of PEP schedules with reduced duration and/or number
of doses compared to the PEP schedules recommended in the
2010 WHO position paper on rabies vaccines [15–21]. Their char-
acteristics are summarized below and detailed study results are
available in Table 3.3.1.1. 1-week, 4 site ID schedule (4-4-4-0-0)
Shantavasinkul et al. evaluated the safety and immunogenicity
of a one-week ID schedule in 131 healthy volunteers [15]. The
study included 3 arms, all which used purified Vero cell rabies vac-
cine (PVRV): (1) a 1-week, 4-site ID schedule in healthy, non-rabies
exposed volunteers; (2) a 1-week, 4-site ID schedule plus equine
rabies immunoglobulin (eRIG) in healthy, non-rabies exposed vol-
unteers; and (3) a Thai Red Cross (TRC) schedule plus eRIG in
patients with category III exposures from suspected rabid animals.
All participants had RVNA concentrations 0.5 IU/ml on days 14
and 28. The proportion of subjects that had antibodyPlease cite this article as: J. Kessels, A. Tarantola, N. Salahuddin et al., Rabies
schedules and the effect of changing administration routes during a single couconcentrations 0.5 IU/ml on day 360 were similar across the
three study arms. The 1-week, 4-site ID schedule showed increased
immunogenicity compared to the 5-visit TRC-ID schedule on days
14 and 28.
Sudarshan et al. evaluated the safety and immunogenicity of
this ID schedule in healthy, non-rabies exposed volunteers [16].
The study had 2 arms using (1) purified chick embryo cell rabies
vaccine (PCECV); and (2) PVRV. All participants had RVNA concen-
trations 0.5 IU/ml at day 14, 28, and 180. The immune response
was comparable to that induced by previously WHO-
recommended PEP schedules. One-year post immunization, 78.9%
of volunteers who received PCECV (arm 1) and 62.5% of those
who received PVRV (arm 2) had RVNA concentrations 0.5 IU/ml.
Volunteers with RVNA concentrations <0.5 IU/ml received booster
doses i.e. 4-site ID vaccination on day 436 ± 16. All who received
booster vaccination had RVNA concentrations 0.5 IU/ml by day
7 following booster vaccination. This quick anamnestic response
to booster vaccination indicates the schedule induced strong
immunological memory. No significant differences were present
in the anamnestic RVNA response to PCECV compared to PVRV.
The schedule was well-tolerated and adverse event rates were rel-
atively low.
Narayana et al. evaluated the ID schedule in patients with cat-
egory II and III exposures from suspected rabid animals [17]. The
patients received either PCECV or PVRV. All subjects followed up
had RVNA titres 0.5 IU/ml at day 14, 90 and 365; and all were
alive and healthy on day 365. Patients with category III exposures
across both study arms received eRIG. No significant difference was
found between RVNA titres of patients who received eRIG com-
pared to those who did not (i.e. patients with category II compared
to category III exposures) or between patients who received PCECV
and eRIG compared to PVRV and eRIG. The incidence of local andpost-exposure prophylaxis: A systematic review on abridged vaccination
rse, Vaccine, https://doi.org/10.1016/j.vaccine.2019.01.041
Table 3
Detailed overview on design, immunogenicity and effectiveness of identified studies on investigational PEP schedules for healthy persons.
Author Year Schedule Route Sites Days Clinic
Visits
Total
Dosage
(mL)
Duration
(days)
Sample
Size
Sample Specifics Vaccine
Used
Serology Results Potency
(IU/mL)
Limitations
and Concerns
Exposure
characteristics
Huang et al.
[18]
2014 1-week/2 and 1
site IM
IM (2-
0-1-
0-0)
0, 7 2 1.5
(0.5 ml
vial)
3.0
(1 ml
vial)
7 181 1. 79 in test group
and 102 in control
group (Essen)
2. 919 blood
samples obtained
out of 1086
sampling events
scheduled due to
poor compliance
by control group at
days 180 and 360
3. All had no prior
antirabies
vaccination
PVRV 1. On day 14, all study
subjects exhibited
RVNA titres >0.5 IU/mL
2. RVNA titres were
maintained in both
groups through days 45
and 180 before
gradually declining
3. The percentage of
subjects positive for
RVNA on day 7 was not
statistically different
between the test and
control groups
4. On day 360, the
percentage of subjects
positive for RVNA in
the variable and control
groups were 93.9% and
100% respectively,
which was statistically
significant
5.5 1. Schedule
tested in
healthy
subjects
2. All study
subjects were
young adults
between 18
and 26 years of
age
3. The long-
term
persistence of
immunity was
slightly
reduced
following the
2-1 schedule
compared with
the five-
injection
schedule
therefore
clinical
research is
needed for
comparison
4. Did not
include vaccine
combined with
RIG
Healthy
volunteers
Naranya et al.
[17]
2015 1-week/4-site ID ID (4-
4-4-
0-0)
0, 3,
7
3 0.4-0.4-
0.4
(total
1.6 ml)
7 90 1. eRIG
administered to all
category III
exposures
2. Randomized
into 2 groups to
receive either
Rabipur or Verorab
3.
Sociodemographic
characteristics
between groups
were similar
4. All had no prior
antirabies
vaccination
Purified
chick
embryo
cell
(Rabipur)
or PVRV
1. Serum samples were
collected on days 0, 14,
90, and 365
2. In the Rabipur group,
the GMT of RVNA was
14.5, 11.78, and
5.96 IU/mL on days 14,
90, and 365
respectively
3. In the Verorab group,
the GMT of RVNA was
14.43, 11.93, and
5.67 IU/mL on days 14,
90, and 365
respectively
4. 100% of the subjects
had adequate >0.5 IU/
mL RVNA
concentrations from
day 14 to day 365
5. Both the vaccines
with or without eRIG
had similar GMT RVNA
concentrations
6.9–7.5 1. Confirmation
of rabies in the
biting animals
was not
possible due to
practical
difficulties
2. Was not
tested in
children,
pregnant, or
lactating
women
Volunteers with
category II or III
animal
bites/exposures
from suspected
rabid animals
(not lab
confirmed)
4
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Shantavasinkul
et al. [15]
2010 1-week/4-site ID ID (4-
4-4-
0-0)
0, 3,
7
3 0.4-0.4-
0.4
(total
1.6 ml)
7 131 1. All had no prior
antirabies
vaccination
2. The
characteristics of
subjects in each
group were similar
in terms of age and
sex
3. Group A
received test
schedule Group B
received test
schedule and eRIG,
and Group C were
those with
category III rabies
exposures and
received TRC-ID
schedule and eRIG
PVRV 1. RVNA levels were
tested on days 0, 7, 14,
28, 90, 180, and 360
2. The overall pattern of
antibody response was
similar in each study
group; highest on days
14 and 28 and slowly
decreased up to day
360
3. All subjects who
received the 4-site ID
schedule had RVNA
levels > 0.5 IU/mL on
days 14 through 90
4. The GMT of RVNA in
the 4-site ID schedule
with and without eRIG
were significantly
higher than the GMTs
from the TRC-ID
schedule on days 14
and 28
5. On day 180, subjects
receiving the TRC-ID
schedule had
significantly higher
GMTs than did the
subjects receiving the
4-site ID schedule with
or without eRIG;
explained by the day 90
booster
6. The percentages of
subjected who had
RVNA levels > 0.5 IU/
mL were not
significantly different
among the 3 groups
from days 0 through
360
9.6 1. Schedule
tested in
healthy
subjects
2. Confirmation
of rabies in the
biting animals
in the control
group was not
possible
Healthy
volunteers
category III
exposed
patients from
suspected rabid
animals in the
control group
(not lab
confirmed)
Sudarshan et al.
[16]
2012 1-week/4-site ID ID (4-
4-4-
0-0)
0, 3,
7
3 0.4-0.4-
0.4
(total
1.6 ml)
7 80 1. All had no prior
antirabies
vaccination
2. The
sociodemographic
characteristics of
the two groups
were similar
3. Subjects were
allocated
randomly to
PCECV or PVRV
test groups
Purified
chick
embryo
cell
(Rabipur)
or PVRV
1. Blood samples were
collected on days 0, 7,
14, 28, 180, and 365
2. All subjects in both
groups had adequate
RVNA
concentrations > 0.5 IU/
mL from day 14 to 180
and the difference of
GMT between the two
groups was not
significant
3. ID booster was given
to those who did not
have adequate RVNA
concentration on day
365 and resulted in a
quick and enhanced
RVNA concentrations
>2.5 1. Schedule
tested in
healthy
subjects
2. Small
sample size
3. Did not
include vaccine
combined with
RIG
Healthy
volunteers
(continued on next page)
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Table 3 (continued)
Author Year Schedule Route Sites Days Clinic
Visits
Total
Dosage
(mL)
Duration
(days)
Sample
Size
Sample Specifics Vaccine
Used
Serology Results Potency
(IU/mL)
Limitations
and Concerns
Exposure
characteristics
Warrell et al.
[19]
2008 1 month/modified
4-site ID
ID (4-
0-2-
0-1)
0, 7,
28
3 0.4-0.2-
0.1
(total
0.7 ml)
28 254 1. The
characteristics of
subjects in each
group were similar
2. Subjects
received one of
four PEP schedules
the 2-site TRC ID,
the 8-site ID
(0.05 ml/site), the
modified 4-site ID,
or standard 5-dose
IM
3. All had no prior
antirabies
vaccination
PVRV 1. RVNA responses
were measured on days
0, 7, 14, 90, and 365
2. All ID schedules
showed similar
immunogenicity
3. The IM schedule gave
the lowest GMTs
4. On day 14, all
subjects had antibody
levels > 0.5 IU/mL
5. The 4-site PEP
schedule is supported
as immunogenic as
current regimens
5.3–8.4 1. Regimen
tested in
healthy
subjects
2. Did not
included
vaccine
combined with
RIG
3. Day 90 dose
Healthy
volunteers
Quiambao et al.
[21]
2008 1 month/modified
4-site ID
ID (4-
0-2-
0-1)
0, 7,
28
3 0.4-0.2-
0.1
(total
0.7 ml)
28 339 1. The
characteristics of
subjects in each
group were similar
2. Subjects
received one of
four PEP schedules
the 8-site ID no
RIG, modified 4-
site ID no RIG, 2-
site ID TRC with
RIG, or a 5-dose
Essen IM without
RIG
3. All had no prior
antirabies
vaccination
PVRV 1. RVNA responses
were measured on days
0, 5, 7, 14, 28, before
the booster at 1 year
and 2 weeks after the
booster
2. By day 14, all
subjects in the 8-site ID
and modified 4-site ID
groups had antibody
levels > 0.5 IU/mL, 1
patient each for the
other groups did not
show a titre > 0.5 IU/ml
3. The GMT of all
groups on day 14 was
above 0.5 IU/mL, the
modified 4-site
regimen showed GMTs
slightly above the TRC,
but this was not
statistically significant
4. Although the 8-site
ID regimen resulted in
higher antibody titres
than the other 3
groups, seroconversion
did not occur any
earlier
5. The 4-site PEP
schedule is supported
as immunogenic as
current regimens
5 IU/
mL
1. Regimen
tested in
healthy
subjects
2. Did not
included
vaccine
combined with
RIG for
investigational
regimen
(modified 4-
site)
3. Day 90 dose
4. Non-peer-
reviewed
journal
Healthy
volunteers
category I and II
patients
exposed to
healthy animals
6
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Ambrozaitis
et al. [20]
2006 1 month/modified
4-site ID
ID (4-
0-2-
0-1)
0, 7,
28
3 0.4-0.2-
0.1
(total
0.7 ml)
28 180 Healthy volunteers
were randomized
to receive a
modified 4-site
regimen with
either 0.1 ml dose
per injection site of
PCECV or PVRV
Purified
chick
embryo
cell and
PVRV
1. RVNA responses
were measured on days
0, 7, 14, 90, and 104
2. By day 14, all 173
subjects reached RVNA
titres above 0.5 IU/mL
3. For 171 of the 173
subjects RVNA titres
remained above 0.5 IU/
mL throughout the
study with a trough on
day 90 when the last ID
dose was given
PCECV
5.53 IU/
ml, PVCV
17.86 IU/
ml
1. Regimen
tested in
healthy
subjects
2. Did not
included
vaccine
combined with
RIG
3. Day 90 dose
Healthy
volunteers
Tarantola et al.
[28],
in
press
1 week 2-site ID
’IPC regimen’
ID (2-
2-2-
0-0)
0, 3,
7
3 0.2-0.2-
0.2
(total
0.6 ml)
7 2,805 255 patients of the
IPC rabies clinic
who sought 3 and
2,497 who
sought  4
sessions of the
updated TRC PEP
schedule (53
received < 3
sessions).
Category III
exposure in 60 and
648 patients who
sought 3 and 4
sessions of the TRC
PEP regimen,
respectively,
including
confirmed rabies
exposure in 90 and
1112 patients,
respectively
PVRV no immunogenicity
data
2.5 IU/
mL
1. Clinical
outcome, no
serology
1066 patients
with category III
bites/exposures
from probable
rabid animals,
no active follow
up
1739 patients
with category III
bites/exposures
from probable
rabid animals,
active follow up
>6 months
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reported for WHO approved schedules.
Overall, the safety and immunogenicity results for the 1-week,
4-site ID schedule are consistent across studies when either PVRV
or PCECV are used. Compared to the updated TRC schedule this
schedule reduces the number of clinic visits to 3 over a single
week.
3.1.2. 1-week IM schedule (2-0-1-0-0)
Huang et al. 2014 evaluated the immunogenicity and safety of a
one-week IM schedule compared to the 5-dose Essen IM schedule
in healthy, non-rabies exposed veterinary students aged 19–
23 years [18]. No RIG was administered. The 1-week IM schedule
demonstrated the same immunogenicity and safety profile as the
5-dose Essen schedule, eliciting RVNA concentrations 0.5 IU/ml
from day 14 onwards until day 180. The use of this schedule could
reduce patients’ expenditure, and potentially improve PEP compli-
ance rates through fewer (2) clinic visits and a shorter course
(7 days). Moreover, this schedule utilizes only three injection sites
and is likely to reduce the frequency of adverse events. However,
Huang et al. concluded that further investigations are necessary
to continue to assess the immunogenicity and clinical effectiveness
of this schedule before making new policy recommendations to
change the current immunization protocols.
3.1.3. Indirect evidence, 1-week IM schedule (1-1-1-0-0)
In view of the lack of additional studies on investigational IM
PEP schedules, indirect evidence was used to evaluate the abridg-
ment of the 4-dose Essen IM schedule to 3 visits and 3 doses (days
0, 3 and 7). Immunogenicity data that compared investigational
schedules to the IM Essen schedule showed adequate antibody
titres after the third dose. Warrell et al. [19] for example included
the comparative immunogenicity data of the 5-dose Essen IM reg-
imen for days 7 and 14. GMTs for all study arms were similar and
0.5 IU/ml on day 14. Nevertheless, clinical outcome data to sup-
port a 1-week, 3-dose IM regimen were not available.
3.1.4. 1-month, modified 4-site ID schedule (4-0-2-0-1)
Ambrozaitis et al. [20] conducted a two-arm study in Lithuania
comparing the modified 4-site ID schedule with a 5-session vac-
cine regimen: 4-site ID administration on day 0, 2-site on day 7
and 1-site on days 28 and 90. Study participants were healthy,
non-rabies exposed individuals receiving either PCECV (n = 91) or
PVRV (n = 89). By day 14 all study participants had RVNA titres
0.5 IU/ml and 99% remained 0.5 IU/ml until day 90. Equivalent
immunogenicity of PCECV versus PVRV use for this schedule was
demonstrated on day 14 and day 90, as geometric mean antibody
titres (GMT) were similar for these WHO pre-qualified vaccines
used.
Warrell et al. evaluated the modified 4-site ID schedule in a
multi-arm, randomized controlled trial involving a total of 254
healthy, non-rabies exposed individuals [19]. The trial used PVRV
in all study arms: (1) modified 4-site ID schedule (4-0-2-0-1-1)
(n = 60); (2) 8-site ID schedule (8-0-4-0-1-1) (n = 65), but with an
ID dose of 0.05 ml per site; (3) 2-site ID TRC schedule (2-2-2-0-
1-1) (n = 66); and (4) 5-dose Essen IM schedule (1-1-1-1-1)
(n = 63). All participants (100%) had RVNA concentrations
0.5 IU/ml by day 14.
Quiambao et al. 2008 conducted a study in 339 healthy individ-
uals and patients who consulted for category I or II exposures to
non-rabid dogs or cats in the Philippines [21]. The study included
4 arms and used PVRV: (1) 8-site ID schedule (n = 96); (2) modified
4-site ID schedule including the day 90 dose (n = 96); (3) 5-dose
Essen IM (n = 97); and (4) TRC schedule (plus eRIG or human rabies
immunoglobulin IM) (n = 99). All subjects (100%) had RVNA titres
0.5 IU/ml by day 14. The GMT of all groups on day 14 wasPlease cite this article as: J. Kessels, A. Tarantola, N. Salahuddin et al., Rabies
schedules and the effect of changing administration routes during a single cou0.5 IU/ml, with the GMT of arm (1) (8-site ID) significantly higher
than all other groups on day 7. The other study arms showed sim-
ilar GMTs on day 14. After 1 year, the GMT of arm (1) was signifi-
cantly higher than in all other groups, and results from arms (2),
(3) and (4) were comparable, with 79–85% of individuals still
showing titres of >0.5 IU/ml).
Compared to the TRC schedule, the modified 4-site ID schedule
requires fewer clinic visits, potentially reduces vaccine wastage in
small clinics and study authors claim a wider margin of safety, if
the patient does not return after the first session (clinical data
not available). In 2007, WHO recommended abandoning the day
90 dose of the TRC and of the modified 4-site ID schedule thereby
reducing the schedules’ duration to 28 days [29].3.1.5. 1-week, 2-site ID (2-2-2-0-0)
A prospective study was conducted with systematic call-back
starting in 2013 of all patients managed at Institut Pasteur Cam-
bodge (IPC) between 2003 and 2014 for a bite by a category III
exposure to a dog with confirmed or suspected rabies [28]. The
study included 1739 eligible participants of all ages with a cate-
gory III exposure to laboratory-confirmed rabid dogs and 1,066
patients bitten by untested but sick-looking dogs. All patients
starting PEP received the updated TRC schedule (PVRV) including
RIG. Clinical outcomes were comparable among those who com-
pleted the recommended schedule and those who terminated the
protocol early, after one week/3 sessions, of their own accord.
These conclusions are supported by preliminary serological out-
come data from another IPC study in patients with confirmed
rabies exposure (Borand et al., manuscript submitted, results par-
tially available in [14]).3.1.6. Evidence on PEP schedules for special populations
Only three recent studies were available which specifically
assess rabies PEP schedules in immunocompromised individuals.
Rahimi et al. [22] found that both immunocompetent and
immunocompromised patients responded similarly to a 5-dose
Essen IM schedule. Although the average antibody titres were
higher in immunocompetent participants, the GMT ranges over-
lapped and were 0.5 IU/ml in both groups, suggesting that the
immune responses were comparable.
Tanisaro et al. [23] evaluated the 5-dose TRC-ID schedule in
haemodialysis patients with end-stage renal failure. All subjects
(n = 14) had adequate antibody responses against rabies 14 days
post vaccination. These results suggest that ID rabies vaccine
administration is immunogenic in haemodialysis patients.
Sirikwin et al. [24] tested the immunogenicity of an 8-site ID
regimen (8-8-8-8-8) in 27 HIV-infected patients. Both, patients
whose CD4+ cell counts were below (n = 9) and above 200 cells
(n = 18) per ml, were included. All had adequate antibody titres
0.5 IU/ml on day 14 after immunization with PCECV. There was
no statistically significant difference in titres between persons with
CD4+ cell count above or below 200 up to day 360. Sirikwin con-
cluded that the 8-site ID regimen may represent an immunogenic
option for HIV-infected patients with CD4+ cell counts below 200.
Anecdotal experiences denote additional rabies PEP schedules that
may be indicated in the above risk groups.
A study conducted in China among pregnant women with sus-
pected rabies virus exposures found both PVRV and PCECV rabies
vaccines to be safe for use in pregnant women, with no rabies cases
reported in any subjects or their newborns [25]. Two recent
reviews on or with reference to rabies vaccines and pregnancy
are available [30,31]. The 2010 WHO position recommended that
any PEP schedule for healthy persons can be used during
pregnancy.post-exposure prophylaxis: A systematic review on abridged vaccination
rse, Vaccine, https://doi.org/10.1016/j.vaccine.2019.01.041
Table 4
Rabies virus neutralizing antibody titres following.
(a) Change in route of administration during the same PEP course. Results table adapted from Ravish et al., 2014 [26]
Day Switch from intradermal route to intramuscular route or vice versa
Geometric mean titre 95% CI Range
14 14.83 13.58–15.63 7.5–22.5
(b) Change in route of administration for booster vaccination (days 0 and 3). Results table adapted from Sudarshan et al., 2006 [27]
Day Intradermal route* Intramuscular routey
Geometric mean titre 95% CI Range Geometric mean titre 95% CI Range
0 0.59 0.50–0.68 0.5–0.8 0.59 0.50–0.71 0.5–1.0
14 8.84 7.58–10.30 7.4–12.4 9.17 7.84–10.70 6.9–12.7
* Previous vaccination by intramuscular route y previous vaccination by intradermal route CI confidence interval.
y Value for test of significance of geometric mean titre between days 0 and 14 was 79.26 for the intradermal and 24.87 for the intramuscular group. The degrees of freedom
were 9 and p value < 0.0001 for both the groups.
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Although the practice of changing product or administration
route during a single PEP course probably occurs, there were only
two recent studies which assessed associated immunogenicity
data [26,27].
Ravish et al. provided supporting evidence that changes in vac-
cine product (n = 43) or the route of administration (n = 47) of
rabies vaccines (n = 24 from ID to IM and n = 23 from ID to IM)
are safe and immunogenic [26]. All participants had antibody titres
0.5 IU/mL on day 14 post-immunization. Detailed immunogenic-
ity data are available in Table 4.
In a slightly different context Sudarshan et al. conducted a study
in 20 volunteers who previously received a full course of PEP [27].
The immune response was assessed by mimicking PEP for previ-
ously immunized people and necessitating a change in route of
administration of PCECV vaccine. It showed that these are safe
and immunologically efficacious following booster vaccination,
even after a change from the ID to the IM route and vice versa.
These new studies and expert knowledge suggest that restart-
ing PEP is not necessary after switching product or administration
route.Table 5
2018 PEP recommendations for non-previously immunized individuals of all age
groups, modified from [34].
Category II exposure Category III exposure
Wound washing and immediate
vaccination:
Wound washing and immediate
vaccination
– 2-sites ID on days 0, 3 and 7 – 2-sites ID on days 0, 3 and 7
– OR 1-site IM on days 0, 3, 7 and
between day 14–28
– OR 1-site IM on days 0, 3, 7 and
between day 14–28
– OR 2-sites IM on day 0 and 1-site
IM on days 7, 21
– OR 2-sites IM on days 0 and 1-
site IM on days 7, 21
RIG is not indicated RIG administration is recommended4. Discussion
Available evidence suggests that current PEP schedules can be
reduced in duration, and in some cases also in number of doses
administered while maintaining immunogenicity and effectiveness
of PEP. The largest amount of published evidence supports the 1-
month modified 4-site ID and 1-week 4-site ID schedules, and fur-
ther research is needed on the potential for reducing dose and
duration of IM schedules, i.e. to 3 doses and/or 1-week duration.
However, the 1-week 2-site ID regimen is supported by compelling
clinical effectiveness and immunogenicity data from Cambodia, a
rabies-endemic country. Reducing the number of clinic-visits and
their associated costs potentially improves patient compliance
[10,28]. The 2018WHO recommendations for ID PEP currently rep-
resent an off-label use in many countries and it will be necessary to
overcome (national) regulatory issues through e.g. regional regula-
tory approaches to accelerate uptake of the 2018 position. How-
ever, countries have already adopted the practice of off-label and
fractional dose use of other vaccines, prior to approval from
national regulatory bodies [32]. Further WHO is in continuous con-
tact with vaccine manufacturers to urge for update of package
inserts which will facilitate uptake of the WHO recommendations.
Although the 1-month modified 4-site ID and 1-week, 4-site ID
schedules are shown to be safe and immunogenic, they may not all
be feasible to implement, or more cost-effective than the currentPlease cite this article as: J. Kessels, A. Tarantola, N. Salahuddin et al., Rabies
schedules and the effect of changing administration routes during a single couupdated TRC-ID schedule. Not everyone agrees on the tolerable
and feasible number of injection sites per visit – especially in a
busy rabies clinic, in small children and among female bite victims
in a conservative society, and using a 4-site injection schedule may
not be fully supported by clinicians in rabies-endemic countries. Of
the new schedules, the 1-week, 2-site ID PEP (IPC) schedule is
therefore likely to be the most acceptable and feasible to
implement.
Modelling work comparing the cost-effectiveness of different
PEP schedules further shows that the 1-week, 2-site ID PEP sched-
ule has the lowest direct costs (i.e. cost of vaccine) than any other
PEP schedule in clinics with 5 new PEP patients per month [33].
PEP schedules that use less vaccine spare cost and may also be crit-
ical to overcome vaccine shortages in settings where vaccine avail-
ability is limited, especially where patients can be pooled for
injections.
In the absence of robust, direct evidence on the effectiveness of
a 3-dose IM regimen and out of caution, a 4-dose Essen IM sched-
ule on days 0, 3, 7 and the last dose between day 14 and 28 was
suggested. The established Zagreb schedule is maintained.
This combined new evidence led to the endorsement of the
2018 WHO recommended PEP schedules for category II and III
exposures [34], as summarized in Table 5.
Most of the included studies did not assess the safety and
immunogenicity of novel PEP schedules for special populations,
such as for infants, pregnant women or immunocompromised per-
sons, such as people infected with HIV. However, the use of PEP in
these subpopulations is highly relevant and was included as a pri-
ority question by the SAGE working group on rabies. Recent publi-
cations on PEP schedules in immunocompromised persons show
limitations and earlier studies in HIV-infected children [35,36]
did not confirm that a higher amount of antigen, such as might
be achieved through administration of supplementary rabies vac-
cine doses, necessarily results in an adequate immune response
in persons with advanced immunosuppression. Nevertheless,post-exposure prophylaxis: A systematic review on abridged vaccination
rse, Vaccine, https://doi.org/10.1016/j.vaccine.2019.01.041
10 J. Kessels et al. / Vaccine xxx (xxxx) xxxstudies on routine vaccines have shown that HIV patients undergo-
ing antiretroviral treatment and monitoring react similarly as non-
HIV infected individuals [37,38]; and that ID immunization was as
immunogenic as IM vaccination in patients with low CD4 counts
who received inactivated influenza vaccines [39,40]. The updated
evidence further confirms that administering rabies vaccines dur-
ing pregnancy is safe, effective, does not interfere with the devel-
opment of the foetus or infant; and should never be withheld.
Although the same product and route of administration should
be used throughout the vaccine course, in many instances it may
become necessary to change the route or product. Evidence from
two studies with limited sample size suggests that changes in the
vaccine product and/or route of administration during the same
PEP course are acceptable in unavoidable circumstances, to pro-
mote completion of the potentially lifesaving PEP schedule. The
findings further add to the consensus that modern, cell culture-
derived rabies vaccines are among the highest immunogenic vacci-
nes known, regardless of administration route or vaccine type used.
Overall, the quality of available evidence on new PEP schedules,
is weakened by the small sample sizes of the reviewed studies, low
numbers of randomized clinical trials, large amounts of clinical
data remaining unpublished and limited geographic representa-
tiveness, as most clinical trials were conducted in South and South
East Asia. The authors note that this systematic review is not
exempt of common bias known from other systematic reviews: Lit-
erature published in languages other than English might only be
partly captured in the databases searched and there are lower
numbers of publications from rabies-endemic, low-income coun-
tries. Considerations on how to assess novel PEP regimens, while
respecting ethical, scientific and health economic evaluation crite-
ria, is published in this special issue [41]. Six of the eight trials on
abridged PEP schedules were conducted only in healthy volunteers
and are not supported by observational data of patients with sus-
pect or confirmed rabies exposures from animal bites. This review
indicates that more studies with larger samples sizes may be
needed to improve the quality of evidence. Trials conducted on
the African continent would be valuable, as the per capita rabies
burden in Africa is large, but rabies vaccine studies from African
countries are underrepresented in the current literature.5. Conclusion
The ID route of administration has been accepted and practised
in many low-income countries for several decades. Several
optional regimens have been studied and proposed, but these
add complexity of choice for the health care giver. Hence, the
2018 WHO position attempts to simplify the regimen without
compromising effectiveness. The evidence available shows that
the 1-week, 4-site ID schedule [15–17], the 1-month modified 4-
site ID schedule [19–21], and the 1-week, 2-site ID schedule
[14,28] are safe and immunogenic. A 1-week schedule also has
obvious advantages of reducing time, cost, improving adherence,
and, for high throughput clinics, reducing the volume of patients
by removing the 1-month dose. Rabies vaccines are safe and effica-
cious to use in pregnant women and should be administered using
any of the recommended schedules.
Adequate immunogenicity data alone are not considered suffi-
cient evidence when trying to reduce the number of visits or doses
in a rabies PEP schedule. Considering clinical outcome data,
immunogenicity, feasibility and cost-effectiveness, the 1-week, 2-
site ID PEP (IPC) schedule best fulfils the above requirements and
is therefore proposed as the or a new WHO-recommended sched-
ule for ID rabies PEP [34]. As the IPC regimen is newly recom-
mended on the basis of clinical outcome and serological data,
formal clinical trial data are lacking for the moment.Please cite this article as: J. Kessels, A. Tarantola, N. Salahuddin et al., Rabies
schedules and the effect of changing administration routes during a single couAn integrated vigilance system should be implemented to
detect rabies deaths among PEP recipients, especially among those
exposed to confirmed rabid or untested, but sick-looking dogs [41].
This will help detect breakdowns in procedure (e.g. vaccine lost,
cold chain), improve safety, and facilitate research. Research on
the potential for further reducing dose and duration of both, IM
and ID schedules, and on the use of rabies PEP in immunocompro-
mised individuals needs to continue. This should be based on the
protocols developed describing the data and sample size needed
(supported by statistical calculations) to recommend a new PEP
schedule [41]. Future research on investigational PEP schedules
using internationally standardized questionnaires and surveillance
methods should consider clinical outcome data, but also cost-
effectiveness, programmatic feasibility and acceptability to
patients and clinicians.
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